ArticleActa obstetricia et gynecologica Scandinavica2026
Menopausal hormone therapy after ovarian cancer: A 10-year survival analysis in premenopausal women.
Article in Acta obstetricia et gynecologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A comprehensive model for gynecologic cancer patients' survivorship care.Gynecologic oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionPremenopausal women treated with bilateral salpingo-oophorectomy (BSO) for ovarian cancer (OC) enter surgical menopause. Our objective was to evaluate whether postoperative systemic menopausal hormone therapy (MHT) after BSO due to treatment for epithelial ovarian cancer (EOC), non-epithelial ovarian cancer (NEOC), or borderline ovarian tumor (BOT) has an impact on long-term overall survival (OS). MATERIAL AND
methodsA nationwide Swedish population-based cohort study of women aged 18-50 diagnosed with OC (FIGO stage I-IV) and treated with BSO between 2008 and 2015, identified from The Swedish Quality Register for Gynecological Cancer. Exposure to postoperative MHT from 1 month before to 5 years after surgery was assessed by linking the cohort to the National Prescribed Drug Register to capture drug dispensing data. Standardized OS was estimated for MHT users and non-users, adjusted for covariates included in multivariable models. EOC, NEOC, and BOT were analyzed separately.
resultsA cohort of 779 premenopausal women with a median age of 45 years at BSO, of whom 472 had an EOC, 68 a NEOC and 239 a BOT, was identified. Median follow-up in the total cohort was 11.7 (9.6-13.6) years. Among women with EOC, 33% were postoperative MHT users. For the EOCs, the 10-year OS for postoperative MHT users versus non-users was 52.4% (95% CI 46.7-58.8) and 51.7% (95% CI 47.4-56.4), respectively. No significant difference in 10-year OS was found between postoperative MHT users and non-users (HR 0.97; 95% CI 0.73-1.30; p = 0.84). Among 367 women with EOC and no residual disease at surgery, there was no difference in 10-year OS between postoperative MHT users and non-users (HR 1.00; 95% CI 0.70-1.43; p = 0.98). For women with a BOT, the 10-year OS was 96.2% (95% CI 91.6-98.2) for postoperative MHT users versus 95.3% (95% CI 87.8-98.2) for non-users. Among women with a NEOC, OS was not analyzed due to the few events.
conclusionsIn this nationwide cohort, postoperative MHT use after surgically treated OC was not associated with impaired 10-year survival. These findings offer reassurance about the safety of MHT in young ovarian cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.